Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Generalized convulsive status epilepticus Clinical criteria: Treatment Phase: Initial treatment Patient must have been assessed to be at significant risk of status epilepticus, AND Patient must have experienced at least one prolonged seizure (greater than 5 minutes duration) requiring emergency medical attention within the previous 5 years. Population criteria: Patient must be at least one year of age. The treatment must initiated by a specialist physician experienced in the treatment of epilepsy. At the time of the authority application, medical practitioners should request the appropriate quantity to cater for the patient's circumstances. Up to a maximum of 10 syringes for each prescription can be authorised for patients with high frequency seizures.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
“Midazolam is a short-acting central nervous system depressant which induces sedation, hypnosis, amnesia and anaesthesia.”
“In normal subjects the mean elimination half-life of midazolam is between 1.4 – 2.4 h and the clearance is in the range of 220 – 470 mL/min.”
“Midazolam is almost exclusively metabolised by CYP3A (primarily CYP 3A4 and also CYP 3A5).”
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.